Online inquiry

IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ211MR)

This product GTTS-WQ211MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL13 gene. The antibody can be applied in Esophagitis eosinophilic research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001354991.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3596
UniProt ID P35225
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ211MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6539MR IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA D2E7
GTTS-WQ7844MR IVTScrip™ mRNA-Anti-RTN4, GSK-1223249(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GSK-1223249
GTTS-WQ12191MR IVTScrip™ mRNA-Anti-CSF2, MORAb-022(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MORAb-022
GTTS-WQ1191MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABP 980
GTTS-WQ10091MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LA480
GTTS-WQ1060MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-621
GTTS-WQ15398MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA TSR-022
GTTS-WQ12300MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MT203
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW